Ovid Therapeutics
Manufacturing · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Hudson Commons 441 9th Ave, New York Cit...Phone Number
(646) 661-7661Website
www.ovidrx.comRevenue
$7.1 MillionStock Symbol
OVIDIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
3
1
1
1
1
About Ovid Therapeutics
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders. Ovid has a broad pipeline of potential first-in-class medicines in development. The Company's most advanced investigational medicine, OV101 (gaboxadol), is currently in clinical development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited for the potential treatment of rare developmental and epileptic encephalopathies (DEEs).Explore more
Ovid Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ovid Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Ovid Therapeutics
Check if Ovid Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Ovid Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Ovid Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on Ovid Therapeutics recently announced quarterly report
Check out if Ovid Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once Ovid Therapeutics has new funding data
Product Launch: Get notified when Ovid Therapeutics launches new products
Recommended Actions
Find VP level buyers at Ovid Therapeutics
Find more new buyers
Compare Similar Companies to Ovid Therapeutics
Compare insights from companies similar to Ovid Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Ovid Therapeutics
$7.1M
11-50
Public
$420.1M
2014
CN
Claude NicaiseChief Operating Officer Head of Research & Development
Company Profile Activity
Activity Insights
Ovid Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Ovid Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Ovid Therapeutics.
Ovid Therapeutics financials insights
Gather financial insights about Ovid Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Series A
$5.1M
Series B
$75M
2017
Series C
$25.9M
Stock Offering
$75M
2019
Stock Offering
$30.5M
Stock Offering
$33.7M
2025
Debt
$175M
Ovid Therapeutics Tech Stack
A closer look at the technologies used by Ovid Therapeutics
See more technologies
Most Recent Scoops
Person-Based
Pharmaceuticals, Clinical Operations
Person-Based
Events, Research & Development
Project
Ovid Therapeutics has announced that OV4071 is not the only KCC2 direct activator in development, with an engine of discovery and further candidates coming, to be discussed at a KCC2 day on April 14, 2026.
Research & Development, Pharmaceuticals
Project
Ovid Therapeutics has announced an efficient path to registration for OV329 in tuberous sclerosis complex and infantile spasms, with signal finding studies establishing signal safety and pediatric dosing to inform both indications.
Pharmaceuticals
Project
Medical Research, Clinical Operations
Ovid Therapeutics News & Media
Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors
NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today announced the appointment of Anna Greka, M.D., Ph.D., to its Board of Directors, effective June 15, 2026.Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today provided business updates including financial results for the first quarter ended March 31, 2026.Ovid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders Transcript
Ovid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders April 14, 2026 9:30 AM EDTCompany ParticipantsMeg Alexander -...Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14
NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today announced the Company will host a KCC2 Deep Dive R&D event highlighting its first-in-class KCC2 portfolio on Tuesday, April 14, 2026, at 9:30 am ET in New York, NY, which will also be webcast simultaneously.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Ovid Therapeutics
Sign Up For FreeTo access detailed company insights
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders. Ovid has a broad pipeline of potential first-in-class medicines in development. The Company's most advanced investigational medicine, OV101 (gaboxadol), is... Read More
